肝移植术后FK506个体化应用的研究进展  

Individual FK506 administration in liver transplantation

作　　者：陆英杰[1] 张金彦[1] 王兆文[1] 彭志海[1] 

机构地区：[1]上海交通大学附属第一人民医院普外科,上海200080

出　　处：《国际外科学杂志》2008年第8期528-531,共4页International Journal of Surgery

基　　金：上海市科学技术委员会科研计划相关项目（No.074119605）

摘　　要：FK506是肝移植术后常用的免疫抑制剂，存在治疗窗狭窄、个体间和个体内变异性大等特点。对移植患者术后血药浓度的监测是目前临床免疫抑制方案调整的主要依据，但仍缺乏较稳定的预见性和指导性。以遗传多态性为基础的药物基因组学的发展为个体化用药提供了更为合理的发展方向。目前国内外的器官移植领域个体化免疫抑制治疗相关研究多围绕细胞色素代谢酶（P450）、P-糖蛋白（PgP）及核内受体编码基因的多态性展开。Tacrolimus, an immunosuppressant used after liver transplantation, has a narrow therapeutic range and its pharmacokinetic variability complicates its daily dose assessment. Therapeutic drug monitoring after liver transplantation, which is the mainstay to clinical immue suppression adjustment, still has its shortage. The development of pharmacogenomics depends on genetic polymorphism provides more reasonable directions to individualized immunosuppressive therapy. At present, the researches of the therapy mainly focus on the genetic polymorphism of coding gene of P450, PgP and nuclear receptor.

关 键 词：FKS06 药物基因组学 P-糖蛋白 细胞色素代谢酶 核内受体 

分 类 号：R657.3[医药卫生—外科学] R969.3[医药卫生—临床医学]